ReviewPharmaceuticals (Basel, Switzerland)2021
Umbilical Cord-Derived Wharton's Jelly for Regenerative Medicine Applications: A Systematic Review.
Review in Pharmaceuticals (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06608134 (Safety and Feasibility of Umbilical Cord Wharton's Jelly Allograft Injections for), which is not on this map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety and Feasibility of Umbilical Cord Wharton's Jelly Allograft Injections for
Who cites it
18 citing papers in PubMed, 31 citations in OpenAlex.
- Comparative Evaluation of Decellularized Human Amniotic Membrane and Wharton's Jelly in a Rat Model of Myocardial Infarction: Experimental Study.Current issues in molecular biology · 2026Article
- An Observational Study of Human Umbilical Cord Tissue Allografts for Paraspinal Muscle and Entheses Defects in the Thoracic and Lumbar Regions.Biomedicines · 2026Article
- Critical evaluation of compositions and clinical relevance of Wharton's jelly-derived biologics.Journal of translational medicine · 2026Review
- An Observational Cohort Study of Wharton's Jelly Tissue Allografts for Posterior Tibial Tendon Degeneration.Biomedicines · 2025Article
- Wharton's Jelly Tissue Allografts for Tearing in the Plantar Fascia: A Case Series.Biomedicines · 2025Article
- Perspectives on the use of decellularized/devitalized and lyophilized human perinatal tissues for bone repair: Advantages and remaining challenges.Materials today. Bio · 2025Article
- Efficacy of Fetal Wharton's Jelly Mesenchymal Stem Cells-Derived Small Extracellular Vesicles in Metabolic Syndrome.Biomolecules · 2025Article
- The Categorization of Perinatal Derivatives for Orthopedic Applications.Biomedicines · 2024Review
- Article
- Cytochalasin B Influences Cytoskeletal Organization and Osteogenic Potential of Human Wharton's Jelly Mesenchymal Stem Cells.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Angiogenesis and Re-endothelialization in decellularized scaffolds: Recent advances and current challenges in tissue engineering.Frontiers in bioengineering and biotechnology · 2023Review
- Temporomandibular Joint Osteoarthritis: Pathogenic Mechanisms Involving the Cartilage and Subchondral Bone, and Potential Therapeutic Strategies for Joint Regeneration.International journal of molecular sciences · 2022Review
- Platelet-Rich Plasma One Week Prior to Hyaluronic Acid vs. Platelet-Rich Plasma Alone for the Treatment of Knee Osteoarthritis.Biomedicines · 2022Article
- The Neural Multilineage Differentiation Capacity of Human Neural Precursors from the Umbilical Cord-Ready to Bench for Clinical Trials.Membranes · 2022Article
- Common Medications Which Should Be Stopped Prior to Platelet-Rich Plasma Injection.Biomedicines · 2022Article
- Decellularized Wharton Jelly Implants Do Not Trigger Collagen and Cartilaginous Tissue Production in Tracheal Injury in Rabbits.Life (Basel, Switzerland) · 2022Article
- Allogenic perinatal tissue for musculoskeletal regenerative medicine applications: a systematic review protocol.Journal of orthopaedic surgery and research · 2022Article
- Allogenic Amniotic Tissue for Treatment of Knee and Hip Osteoarthritis.Pharmaceuticals (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Musculoskeletal ailments affect millions of people around the world and place a high burden on healthcare. Traditional treatment modalities are limited and do not address underlying pathologies. Mesenchymal stem cells (MSCs) have emerged as an exciting therapeutic alternative and Wharton's jelly-derived mesenchymal stem cells (WJSCs) are some of these. This review reports the clinical and functional outcomes of the applications of WJSCs in orthopedic surgery. A systematic review was conducted utilizing the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. The studies that used culture-expanded, mesenchymal stem or stromal cells, MSCs and/or connective tissues procured from Wharton's jelly (WJ), from January 2010 to October 2021, were included. Conventional non-operative therapies and placebos were used as comparisons. Six studies that directly discussed WJSCs use in an animal model or the basic scientific testing using an injury model were identified. Five publications studied cartilage injury, three studied degenerative disc disease, one was related to osteoarthritis, and one was related to osteochondral defects. The results of these studies suggested the benefits of WJSCs in the management of these orthopedic pathologies. To adequately assess the safety and efficacy of WJSCs in orthopedic surgery, further randomized controlled clinical studies are necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.